Alcon Inc (ALC)
80.35
-0.62
(-0.77%)
USD |
NYSE |
May 08, 16:00
80.36
0.00 (0.00%)
Pre-Market: 20:00
Alcon Revenue (Quarterly): 2.352B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.352B |
September 30, 2023 | 2.329B |
June 30, 2023 | 2.422B |
March 31, 2023 | 2.352B |
December 31, 2022 | 2.171B |
September 30, 2022 | 2.14B |
June 30, 2022 | 2.217B |
March 31, 2022 | 2.189B |
December 31, 2021 | 2.149B |
September 30, 2021 | 2.102B |
June 30, 2021 | 2.11B |
March 31, 2021 | 1.93B |
Date | Value |
---|---|
December 31, 2020 | 1.94B |
September 30, 2020 | 1.838B |
June 30, 2020 | 1.214B |
March 31, 2020 | 1.841B |
December 31, 2019 | 1.913B |
September 30, 2019 | 1.868B |
June 30, 2019 | 1.903B |
March 31, 2019 | 1.824B |
December 31, 2018 | 1.791B |
September 30, 2018 | 1.762B |
June 30, 2018 | 1.82B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.214B
Minimum
Jun 2020
2.422B
Maximum
Jun 2023
2.052B
Average
2.11B
Median
Jun 2021
Revenue (Quarterly) Benchmarks
AC Immune SA | 16.70M |
CRISPR Therapeutics AG | 200.00M |
Addex Therapeutics Ltd | 0.1731M |
NLS Pharmaceutics Ltd | -- |
Molecular Partners AG | 1.164M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 427.00M |
Total Expenses (Quarterly) | 2.144B |
EPS Diluted (Quarterly) | 0.86 |
Enterprise Value | 43.26B |
Gross Profit Margin (Quarterly) | 54.85% |
Profit Margin (Quarterly) | 18.15% |
Earnings Yield | 2.44% |
Operating Earnings Yield | 2.61% |
Normalized Earnings Yield | 2.439 |